Atropine-Associated Central Anticholinergic Syndrome during Carotid Artery Stenting: A Case Report
- 1Department of Neurology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea
Abstract
Acute neurobehavioral deterioration during carotid artery stenting (CAS) requires prompt evaluation for serious neurological complications. We report a patient in their 70s who developed profound hyperactive delirium approximately 15 minutes after receiving prophylactic intravenous atropine (0.25 mg) during CAS. The episode was characterized by severe agitation, bilateral mydriasis, and facial flushing without focal neurological deficits. Repeated angiography and subsequent neuroimaging showed no evidence of thromboembolism, intracranial hemorrhage, cerebral edema, or cerebral hyperperfusion. Contrast-induced encephalopathy and cerebral hyperperfusion syndrome were considered but were less consistent with the overall clinical, temporal, and radiographic findings. The patient returned to neurological and cognitive baseline approximately 16 hours after symptom onset without specific antidotal treatment. The close temporal relationship to atropine exposure and characteristic neurobehavioral and autonomic features favored atropine-associated central anticholinergic syndrome, which should be considered in the differential diagnosis of acute neurobehavioral deterioration during CAS.
Related
- Antipsychotic-Induced Parkinsonism With Concurrent Benztropine-Associated Anticholinergic Effects in a Community Emergency Department Setting: A Case Report
- A Diphenhydramine Overdose Mimicking Encephalitis, Complicated by Acute Kidney Injury Associated with Anticholinergic Urinary Retention: A Case Report
- Pupillary signs are associated with subsequent Hirschsprung disease diagnosis and malignant adrenal neoplasm in congenital central hypoventilation syndrome
- Adjunctive iliac vein stenting for May-Thurner-associated lower-extremity phlebolymphedema: a dual-center retrospective cohort study
- Delayed-onset central neurotoxic syndrome with predominant cerebellar dysfunction following combined chlorpyrifos and cypermethrin poisoning: a case report
BibTeX
@article{baek2026atropineassociated,
title = {{Atropine-Associated Central Anticholinergic Syndrome during Carotid Artery Stenting: A Case Report}},
author = {Jang-Hyun Baek},
journal = {Neurointervention},
year = {2026},
month = oct,
doi = {10.5469/neuroint.2026.01158},
url = {https://doi.org/10.5469/neuroint.2026.01158},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Atropine-Associated Central Anticholinergic Syndrome during Carotid Artery Stenting: A Case Report
AU - Jang-Hyun Baek
PY - 2026
DA - 2026/10/15
JO - Neurointervention
DO - 10.5469/neuroint.2026.01158
UR - https://doi.org/10.5469/neuroint.2026.01158
AB - Acute neurobehavioral deterioration during carotid artery stenting (CAS) requires prompt evaluation for serious neurological complications. We report a patient in their 70s who developed profound hyperactive delirium approximately 15 minutes after receiving prophylactic intravenous atropine (0.25 mg) during CAS. The episode was characterized by severe agitation, bilateral mydriasis, and facial flushing without focal neurological deficits. Repeated angiography and subsequent neuroimaging showed no evidence of thromboembolism, intracranial hemorrhage, cerebral edema, or cerebral hyperperfusion. Contrast-induced encephalopathy and cerebral hyperperfusion syndrome were considered but were less consistent with the overall clinical, temporal, and radiographic findings. The patient returned to neurological and cognitive baseline approximately 16 hours after symptom onset without specific antidotal treatment. The close temporal relationship to atropine exposure and characteristic neurobehavioral and autonomic features favored atropine-associated central anticholinergic syndrome, which should be considered in the differential diagnosis of acute neurobehavioral deterioration during CAS.
SN - 2093-9043
SN - 2233-6273
ER -